Download ODDP 2014 Course schedule

ODDP 2014 Course schedule
Last updated: November 3, 2014
Wednesday, November 26
Chairmen: Rob Berg & Eric van der Putten
09:00-10:00
A1. Course introduction
Marinus Lobbezoo, Senior Biomedical Consultant / Course chair, Congress by
design, Harmelen, The Netherlands
10:00-11:10
A2. Carcinogenesis & tumor cell biology
Remond Fijneman, Geneticist, VU University Medical Center, Amsterdam, The
Netherlands
11:10-11:30
Break
11:30-12:30
A3. Oncopathology: Diagnosing cancer
Paul van Diest, Professor of Pathology, University Medical Center, Utrecht, The
Netherlands
12:30-13:30
Lunch
13:30-14:45
A4. Essentials of medical oncology
Jan Vermorken, Professor of Medical Oncology, Antwerp University, Edegem,
Belgium
14:45-15:00
Break
15:00-16:15
A5. Essentials of hemato-oncology
Marie José Kersten, Hematologist, Academic Medical Center, Amsterdam, The
Netherlands
16:15-16:45
Break (with snacks)
16:45-18:15
A6. Tumor immunology and immunotherapy
A6.1 Tumor immunology
Kees Melief, Professor of Immunohematology, Leiden University Medical Center,
Leiden, The Netherlands
A6.2 Malignant melanoma: Paradigm of immunological treatment strategies
Winald Gerritsen (TBC)
18:15
Adjourn day 1
Thursday, November 27
Chairmen: Marinus Lobbezoo & Rob Berg
09:00-10:00
B1. Anticancer drug development: The regulatory environment
Adriaan Fruijtier, Director, Regulatory Affairs, CATS Consultants, Dietmannsried,
Germany
10:00-11:00
B2. Preclinical development of anticancer agents
Kate Owen, Medicine and Science Director, AstraZeneca, Macclesfield, Cheshire,
UK
11:00-11:45
B3. Group Exercises, Preclinical Development
11:45-12:15
Discussion Group Exercises
12:15-13:15
Lunch
Oncology Drug Development in Practice
Amsterdam, The Netherlands, November 26-28, 2014
www.congressbydesign.com/oddp-2014
13:15-14:15
B4. Identification and development of molecular diagnostics and biomarkers for
targeted cancer therapeutics
Alain van Gool, Professor and Head Radboud Center for Proteomics, Glycomics &
Metabolomics, Radboud University Medical Center, Nijmegen, The Netherlands
14:15-15:30
B5. Early-phase clinical studies (phase 1, phase 1 expansion cohorts, phase 1/2
studies)
Ferry Eskens, Medical Oncologist, Erasmus Medical Center, Rotterdam, The
Netherlands
15:30-16:15
B6. Group Exercises, Phase 1 studies
16;15-16:45
Discussion Group Exercises
16:45-17:45
B7. Phase I studies of combinations of targeted therapies
Robin van Geel & Jan Schellens, Netherlands Cancer Institute, Amsterdam, The
Netherlands
17:45-18:30
Break
18:30-20:00
B8. Evening session with food and beverages
Drug development in oncology: small biotech and global pharmaceutical companies
perspectives,
Speakers/discussants:
20:00

Glen Clack, Senior Medical Director, Oncology Translational Medicine Unit,
AstraZeneca, Alderley Park, Cheshire, UK

Ton Logtenberg, Chief Executive Officer, Merus, Utrecht, The Netherlands
Adjourn day 2
Friday, November 28
Chairmen: Eric van der Putten, Marinus Lobbezoo
09:00-10:30
B9 (part 1). Late-phase clinical development
Eric van der Putten, Oncology Drug Development Expert, Leiderdorp The
Netherlands
10:30-10:45
Break
10:45-11:45
B10. Biostatistics in oncology clinical trials (including adaptive trial designs)
Wouter Wijker, Biostatistician, Auxiliis Clinical Development, Budapest, Hungary
11:45-12:45
B9 (part 2). Late-phase clinical development
Eric van der Putten
12:45-14:00
B11. Group Exercises, Late-phase development (lunch packs )
14:00-14:30
Discussion Group Exercises
14:30-15:30
B12. Post-registration drug development in oncology: Aims, study designs,
organization, regulatory issues
Geraldine Vink, Program Manager Colorectal Cancer Registry, IKNL, The
Netherlands
15:30-16:00
B13. Closing session: Take home messages & overall evaluation
Eric van der Putten, Marinus Lobbezoo
16:00
Adjourn
Oncology Drug Development in Practice
Amsterdam, The Netherlands, November 26-28, 2014
www.congressbydesign.com/oddp-2014